To investigate whether the combination of fluoro-2-deoxy-d-glucose (FDG) PET measures with the APOE genotype would improve prediction of the conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD). After 1 year, 8 of 37 patients with MCI converted to AD (22%). Differences in baseline regional glucose metabolic rate (rCMRglc) across groups were assessed on a voxel-based basis using a two-factor analysis of variance with outcome (converters [n = 8] vs nonconverters [n = 29]) and APOE genotype (E4 carriers [E4+] [n = 16] vs noncarriers [E4-] [n = 21]) as grouping factors. Results were considered significant at p < 0.05, corrected for multiple comparisons. All converters showed reduced rCMRglc in the inferior parietal cortex (IPC) as compared with the nonconverters. Hypometabolism in AD-typical regions, that is, temporoparietal and posterior cingulate cortex, was found for the E4+ as compared with the E4- patients, with the E4+/converters (n = 5) having additional rCMRglc reductions within frontal areas, such as the anterior cingulate (ACC) and inferior frontal (IFC) cortex. For the whole MCI sample, IPC rCMRglc predicted conversion to AD with 84% overall diagnostic accuracy (p = 0.003). Moreover, ACC and IFC rCMR...Continue Reading
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study
Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype
The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease
Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment
Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET)
The effect of APOE epsilon4 allele on cerebral glucose metabolism in AD is a function of age at onset
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies
Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD
Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study
Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia
Education and occupation provide reserve in both ApoE ε4 carrier and noncarrier patients with probable Alzheimer's disease
Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease
Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly.
Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease
Apolipoprotein ε4-allele as a significant risk factor for conversion from mild cognitive impairment to Alzheimer's disease: a meta-analysis of prospective studies
Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies
Decreased cortical glucose metabolism in converters from CDR 0.5 to Alzheimer's disease in a community: the Osaki-Tajiri Project
Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease)
Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease
Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden
Topographic patterns of brain functional impairment progression according to clinical severity staging in 116 Alzheimer disease patients: FDG-PET study
Preliminary evidence of validity of the revised criteria for Alzheimer disease diagnosis: report of 2 cases
Arterial spin labeling MRI: an emerging biomarker for Alzheimer's disease and other neurodegenerative conditions
Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment
Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease
The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons
Progression from amnesic mild cognitive impairment to Alzheimer's disease: ESR1 and ESR2 polymorphisms and APOE gene.
Latent profile analysis in frontotemporal lobar degeneration and related disorders: clinical presentation and SPECT functional correlates
New computer-aided diagnosis of dementia using positron emission tomography: brain regional sensitivity-mapping method
Reference cluster normalization improves detection of frontotemporal lobar degeneration by means of FDG-PET
Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-β and cerebrovascular pathology
Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment
Alzheimer's Disease: APOE
Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.
Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.
Alzheimer's Disease: Genetics
Alzheimer's disease is a neurodegenerative disease. Discover genetic and epigenetic aspects of Alzheimer’s disease, including genetic markers and genomic structural variations with this feed.
Alzheimer's Disease: Neuroimaging
Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.